

4DMedical webinar

30th November 2023

Melbourne, Australia, 30th November 2023: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) is pleased to invite shareholders, investors and interested parties to its investor webinar hosted by the Managing Director and Chief Executive Officer, Dr Andreas Fouras.

4DMedical will hold an investor webinar on Friday, 1 December 2023 at 11am AEDT, where Dr Andreas Fouras will discuss the Company’s recent announcements.

Investor Webinar Registration Details

An investor webinar with Dr Andreas Fouras, Managing Director and Chief Executive Officer of 4DMedical will be held at 11am AEDT on Friday, 1 December 2023.

Please register in advance using the following links:

Phone registration: <https://s1.c-conf.com/diamondpass/10035500-fmbdg1.html>

Webcast: <https://ccmediaframe.com/?id=cHzJzDIg>

After registering, you will receive a confirmation email containing information about joining the webinar or dial-in details for those who would prefer to join by telephone.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Chief Financial Officer
Simon Glover
sglover@4dmedical.com

Administration

Company Secretary
Naomi Lawrie
companysecretary@4dmedical.com

Media Enquiries

The Capital Network (TCN)
Julia Maguire
julia@thecapitalnetwork.com.au

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) - the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing clinical imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit www.4dmedical.com.